Price Performance of ADMA Biologics, Inc. (ADMA)
ADMA Biologics, Inc. (NASDAQ:ADMA) has had quite a remarkable price journey over the past year. During the past 12 months, its highest price was $6.96, which this stock reach on 09/06/18, compared to its lowest price during that period – which was $2.08 on 09/06/18.
At the end of the most recent trading day, ADMA Biologics, Inc. closed at $3.31. The stock began the trading session at $3.55 and hit a high of $3.64. The lowest price during the trading day was $3.29.
The shares of this company, which operates in the healthcare sector, reached a trading volume of about 624,185 throughout the day, which was clearly higher than the average daily volume for these shares.
At the time of writing, this publicly-traded organization holds a total market value of 151.13M, with 295 employees on its payroll.
Continuing in the same vein, and taking into account all the analyst ratings for shares of ADMA Biologics, Inc. (NASDAQ:ADMA), the mean rating for this stock is 1.86. How is that calculated? Well, 1 analysts has given this company a BUY rating, 6 are rated it as OUTPERFORM, 0 have recommended that investors HOLD, 0 are considering it an UNDERPERFORM and 0 have recommended that owners of these shares SELL.
A month ago, 1 analysts thought this stock was a BUY, 6 of them posted an OUTPERFORM rating, 0 analysts recommended to HOLD this stock, 0 of them provided an underperform rating and 0 rated it as a Sell.
For ADMA stock, the reported Earnings Per Share trailing twelve months is sitting at 36.60%. Meanwhile, operating margin is currently observed to be and its Gross Margin trailing twelve months is -72.40%.
This company’s 100-day moving average was 4.03, while its price change was posted at -2.30. Similarly, ADMA Biologics, Inc. (NASDAQ:ADMA) experienced a 100-day Percent movement of -41.00% with a trading volume reaching 381,271.
Continuing to look at similarly important data, this stock’s distance from its 200-day Simple Moving Average, or SMA 200, is -31.14% at the time of writing. This organization’s revenue over the trailing twelve months (TTM) of active operations is 24.90M, considering the fact that it was able to rack up the income of -$60.70M through that period of time.
Additionally, if we divide an organization’s current total liabilities by its present stockholder equity, we get a number called the Total Debt to Equity Ratio (also called the D/E Ratio), which is a leading tactic for determining how financially strong the company is. This metric just illustrates how much debt an organization is using to support its assets in relation to how much its shareholder’s equity is worth. ADMA’s Total Dept/Eq ratio is sitting at 1.18 at the time of writing, while its long-term Dept/Eq ratio is 1.18
While maintaining our attention on the Technical analysis of ADMA Biologics, Inc. (NASDAQ:ADMA), during the last 50 days, its Raw Stochastic average was observed 39.06%, representing an improvement from this organization’s 20-day Raw Stochastic average – which was posted 1.67%. During the last 20-days time span, this firm’s Stochastic %K was 5.57% and its Stochastic %D was noted 15.38%.
We can take a look at observable moving trends ADMA Biologics, Inc. (NASDAQ:ADMA) stock by taking a deep at its previous price journey. This particular stock’s current year-to-date (YTD) price performance is standing at 38.49%. Meanwhile, during the past six months of trading, this stock has deteriorated to -49.00%, along with a full-year performance of -33.40%. This company’s shares increased nearly 8.19% during the last 7-day stretch and fell -17.04% over the last 30 days.